. Author manuscript; available in PMC: 2015 Apr 9.

Published in final edited form as: Health Econ. 2013 Oct 9;23(3):359–373. doi: 10.1002/hec.2996

Table II.

Predicted impact of generic group atypical antipsychotic drugs (AADs) compared with branded group AADs on average number of hospitalizations in 12 months following initiation of therapy

	All hospitalizations	Schizophrenia-related hospitalizations
Group	Mean (95% CI)	Mean (95% CI)
All patients (ATE)	0.35 (0.02, 0.67)	−0.07 (−0.28, 0.10)
Patients initiating therapy with generic group (TT)	0.17 (−0.17, 0.44)	−0.15 (−0.38, −0.03)
Patients initiating therapy with branded group (TUT)	0.61 (0.29, 1.05)	0.002 (−0.13, 0.22)
TT—ATE	−0.18 (−0.13, −0.28)	−0.08 (−0.04, −0.12)

ATE, average treatment effect; TT, effect on the treated; TUT, effect on the untreated.